Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 13, 2018 - Issue
Submit an article Journal homepage
42
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan

Hideyasu Yamada1 Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan, [email protected];2 Department of Respiratory Medicine, Hitachinaka General Hospital, Hitachi Ltd, Hitachinaka, Ibaraki, Japan, [email protected]Correspondence[email protected]
,
Norihito Hida2 Department of Respiratory Medicine, Hitachinaka General Hospital, Hitachi Ltd, Hitachinaka, Ibaraki, Japan, [email protected]
&
Nobuyuki Hizawa1 Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan, [email protected]
Pages 3141-3147 | Published online: 08 Oct 2018

References

  • JiangZKnudsenNHWangGGenetic control of fatty acid β-oxidation in chronic obstructive pulmonary diseaseAm J Respir Cell Mol Biol201756673874828199134
  • CalzettaLRoglianiPFaccioloFRendinaECazzolaMMateraMGPharmacological characterization of the interaction between umecli-dinium and vilanterol in human bronchiEur J Pharmacol201781214715428716723
  • CalzettaLOraJCavalliFRoglianiPO’DonnellDECazzolaMImpact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysisRespir Med201712918919828732830
  • CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
  • Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseBethesda, MDGOLD2017
  • ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacol Rev200658362168116968952
  • CazzolaMCalzettaLPageCPPharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchiEur J Pharmacol201474513514325446566
  • CazzolaMCalzettaLPuxedduEPharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cellsRespir Res20161717027296533
  • RoglianiPCalzettaLOraJPuxedduECazzolaMMateraMGClinical synergism of LABA/LAMA combinations in COPD patientsPresented at: ERS CongressSeptember 11, 2017Milan
  • Guideline of respiratory function tests-spirometry, flow-volume curve, diffusion capacity of the lungNihon Kokyuki Gakkai Zasshi2004Suppl156
  • JonesPWBrusselleGdal NegroRWProperties of the COPD assessment test in a cross-sectional European studyEur Respir J2011381293521565915
  • JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD Assessment TestEur Respir J200934364865419720809
  • FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
  • VinckenWAumannJChenHHenleyMMcbryanDGoyalPEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 studyInt J Chron Obstruct Pulmon Dis20149921522824596459
  • BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
  • BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
  • CalverleyPMAAnzuetoARCarterKTiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trialLancet Respir Med20186533734429605624

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.